Roxana Dronca, MD
Enriched profileChair, Hematology/Oncology, Florida · Mayo Clinic in Florida
Roxana Dronca is Chair, Hematology/Oncology, Florida at Mayo Clinic in Florida. OpenAlex indexes 248 publications with 13,753 citations (h-index 41); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 23 Oct 2026
Roxana Dronca, M.D., is Chair, Hematology/Oncology, Florida at Mayo Clinic in Florida (Jacksonville, Florida). The public record shows 248 publications with 13,753 citations (h-index 41), centered on Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 8 companies.
- Most recent indexed publication: 2026 · Cancer research communications
- Top research focus: Cancer Immunotherapy and Biomarkers
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 79.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
Updated 23 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20254 payments$19,235openpaymentsdata.cms.gov ↗
- Immunocore LimitedProgram year20256 payments
- E.R. Squibb & Sons, L.L.C.Program year20242 payments
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.8%PD-1 inhibitor48%Pembrolizumab100%Part B, office-administered≥13 patientsNucleoside Metabolic Inhibitor1.2%Fluorouracil100%Part B, office-administered≥12 patients+ 1 more class in this area
Metabolism & gastrointestinal
42%Other antiemetics33.9%Fosaprepitant100%Part B, office-administered≥11 patientsSerotonin-3 Receptor Antagonist7.8%Ondansetron hydrochloride100%Part B, office-administered≥50 patients+ 1 more class in this area
Sensory organs
7.8%Corticosteroid7.8%Dexamethasone sodium phosphate100%Part B, office-administered≥40 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 23 Oct 2026
70 congress contributions (2013–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 2107: Genomic landscape of melanoma brain metastases: Real-world analysis and comparison with public melanoma cohorts.
AACR Annual Meeting
AACR2026Co-author - Abstract 2382: Achieving prostate cancer equity globally: Multinational advances from the iCCaRE consortium
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Advancing Prostate Cancer Survivorship through Transatlantic Consortium Science: The iCCaRE Initiative.
Cancer research communications
Article2026
Most-cited works
by citation count (OpenAlex)- 01Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaArticle3,396 citations2013
- 02
- 03Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaArticle1,069 citations2016
- 04
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/roxana-dronca-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania (corroborates registry credential M.D.)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practiceupdate.com ↗
Editorial & leadership roles
journal and society appointments- Member
Mayo Clinic Cancer Center Practice Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
Secondary affiliations
appointments beyond the home institution- Director
Mayo Clinic Comprehensive Cancer Center, Florida Cancer Programs
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →alumniassociation.mayo.edu ↗ - Professor of oncology
Mayo Clinic College of Medicine and Science
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practiceupdate.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Thomas Brott, MD
Mayo Clinic in Florida
Keith Oken, MD
Mayo Clinic in Florida
Ruqin Chen, MD
Mayo Clinic in Florida
Robert Smallridge, MD
Mayo Clinic in Florida
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Omid Hamid, MD
The Angeles Clinic and Research Institute
Mario Sznol, MD
University of Miami Miller School of Medicine